Ozempic vs Wegovy: Understanding the Differences Between Two Semaglutide Products

Ozempic and Wegovy both contain semaglutide and are both manufactured by Novo Nordisk. The confusion between them is understandable: they are pharmacologically identical molecules delivered via the same route (subcutaneous injection) on the same schedule (once weekly). The key differences are the approved indication, maximum dose, and pen presentation. Ozempic is approved for type 2 diabetes (and cardiovascular risk reduction in diabetic patients) with doses up to 2 mg. Wegovy is approved for chronic weight management (and cardiovascular risk reduction in overweight/obese patients without diabetes) with doses up to 2.4 mg. They are classified as separate products by the FDA and cannot be substituted by pharmacies — a prescription for Ozempic cannot be filled with Wegovy, and vice versa.

Novo Nordisk developed Wegovy as a separate product for weight management for both regulatory and commercial reasons. The FDA requires separate clinical trials and approval for each indication. The STEP trial program established the efficacy and safety of semaglutide 2.4 mg specifically for weight management, while the SUSTAIN program did the same for lower doses in type 2 diabetes. The higher 2.4 mg dose was designed specifically to optimize weight loss, which is why Wegovy goes to a higher dose than Ozempic. Having separate products also allows different pricing, marketing, and formulary positioning. This separation creates challenges for patients who may benefit from the medication but face different insurance coverage depending on which product is prescribed.

The most practical difference between Ozempic and Wegovy for many patients is insurance coverage. Ozempic is classified as a diabetes medication and is widely covered by commercial insurance plans and many Medicare Part D plans, typically requiring only that the patient has a documented diagnosis of type 2 diabetes and has tried metformin first. Wegovy, classified as an anti-obesity medication, faces much more restrictive coverage. Many commercial plans exclude weight management drugs entirely, and Medicare Part D has historically been prohibited from covering them. This coverage gap has driven significant off-label prescribing of Ozempic for weight loss, contributing to shortages that have affected diabetic patients who depend on the medication. The SELECT trial cardiovascular data has helped Wegovy gain broader coverage, but significant gaps remain.

• Ozempic: Broadly covered for T2D; may require prior auth and metformin step therapy
• Wegovy: Coverage varies widely; many commercial plans exclude anti-obesity meds
• Medicare Part D: Generally covers Ozempic; historically does not cover Wegovy
• Employer plans: Increasingly covering Wegovy post-SELECT trial data
• Manufacturer savings: Both have copay cards for commercially insured patients
• Appeal option: Wegovy denials can be appealed using SELECT cardiovascular data

The answer depends primarily on your diagnosis and treatment goals. If you have type 2 diabetes, Ozempic is the appropriate product and will generally be covered by insurance. If your primary goal is weight management without diabetes, Wegovy is the FDA-approved option, though coverage may be a challenge. If you have both diabetes and obesity, either product could be appropriate, and the choice often comes down to insurance coverage and prescriber preference. Some patients with diabetes are prescribed Ozempic at 2 mg for both glycemic control and weight management, while others receive Wegovy for the higher 2.4 mg dose. It is important to work with your healthcare provider to determine which product is medically appropriate and then navigate the insurance landscape accordingly.